|
Circadian clock gene PER1 mutations in colorectal cancer (CRC). |
|
|
Travel, Accommodations, Expenses - Amgen; Bayer |
|
|
Employment - Caris Life Sciences |
|
|
No Relationships to Disclose |
|
|
Honoraria - Baxter; Biothera; Forty Seven; Immunocare Therapies; kanghong Pharma; Merck; Merck KGaA; Merrimack; Pfizer; Taiho Pharmaceutical; Targovax |
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Amgen; Baxter; Merck KGaA; Sanofi |
|
|
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Halozyme; Ipsen; Merck; Novartis; Rafael Pharmaceuticals; Sanofi |
Consulting or Advisory Role - Celgene; Gilead Sciences; Halozyme; Ipsen; Merck; Merrimack; novartis |
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Celgene; Ipsen; Merck |
Research Funding - Bayer (Inst); Genentech (Inst); Immunomedics (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst) |
Other Relationship - Halozyme |
|
|
Consulting or Advisory Role - Caris Life Sciences |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - bioTheranostics; Merrion |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Ipsen; Taiho Pharmaceutical |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene; Genentech/Roche; Ipsen; Ipsen |
|
|
|
Employment - Benchling (I) |
Stock and Other Ownership Interests - Benchling (I) |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Endocyte; GE Healthcare; Merck; Merrimack; Personal Genome Diagnostics; Siemens Healthcare Diagnostics; Taiho Pharmaceutical |
Speakers' Bureau - GE Healthcare |
Research Funding - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Caris Life Sciences; Eisai; H3 Biomedicine; Inovio Pharmaceuticals; Karyopharm Therapeutics; Merrimack; Novartis; OncoMed; Plexxikon; Taiho Pharmaceutical |
Travel, Accommodations, Expenses - Caris Life Sciences; Endocyte; GE Healthcare; Merrimack |
|
|
Employment - Caris Life Sciences |
Honoraria - Amgen; Bayer/Onyx; Caris Life Sciences; Celgene; Genentech/Roche; Taiho Pharmaceutical |
Consulting or Advisory Role - Amgen; Bayer/Onyx; Caris Life Sciences; Celgene; Genentech/Roche; Taiho Pharmaceutical |
Speakers' Bureau - Amgen; Bayer/Onyx; Celgene; Genentech/Roche; Taiho Pharmaceutical |
Research Funding - Amgen (Inst); Bayer/Onyx (Inst); Boehringer Ingelheim (Inst); Genentech/Roche (Inst); MedImmune (Inst); Pfizer (Inst) |
|
|
Stock and Other Ownership Interests - OncoCyte |
Honoraria - Genentech/Roche |
Consulting or Advisory Role - Merck Sharp & Dohme; Merrimack |
Research Funding - Merrimack (Inst) |
Patents, Royalties, Other Intellectual Property - Exelixis |
Travel, Accommodations, Expenses - Merrimack |
|
|
Honoraria - Bayer; Boehringer Ingelheim; Merck Serono; Roche |
Consulting or Advisory Role - Bayer; Merck Serono; Pfizer; Roche |
Travel, Accommodations, Expenses - Bayer; Merck Serono; Roche |